Non-alcoholic Steatohepatitis - Global Markets to 2023: A $10 Billion Opportunity - ResearchAndMarkets.com

December 6, 2018

DUBLIN--(BUSINESS WIRE)--Dec 6, 2018--The “Global Non-alcoholic Steatohepatitis Market - by Drug Type, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2017-2023)” report has been added to ResearchAndMarkets.com’s offering.

The global non-alcoholic steatohepatitis market will reach 10,032.36 million USD by 2023 from 4,050.87 million USD in 2017 with a CAGR of 16.32% during the period.Increasing cases of diabetics and obesity is the major factor driving the growth of the market. Growth in demand for NASH therapeutics and rise in prevalence of NASH are the factors driving the market. However, lack of diagnostic technologies for NASH is hampering the market growth.

Asia-Pacific will grow with high CAGR owing to growth in diagnostic techniques, rise in prevalence NASH and developing healthcare infrastructure. North America held largest share in the market due to prevalence of NASH and presence of pipeline drugs.

Industry Trends and Updates

AstraZeneca licensed IONIS-AZ6-2.5-LRx, NASH drug from Ionis Pharmaceuticals, Inc. for USD 30 million.Allergan acquired Tobira Therapeutics and Akarna Therapeutics, which provides Allergan a readymade pipeline for the potentially lucrative NASH market.Companies ProfiledAstraZenecaIntercept PharmaceuticalGalmed PharmaceuticalGenfitAllerganGilead ScienceZydus CadilaImmuronConatus PharmaceuticalNovo NordiskEnzo BiochemRaptor PharmaceuticalTobira TherapeuticsPrometheus LaboratoriesSiemens Healthcareand more...

Key Topics Covered

1. Research Methodology

2. Executive Summary

3. Market Overview

4. Market Dynamics

5. Global Non-alcoholic Steatohepatitis Market Segmentation, Forecasts and Trends - by Drug

6. Global Non-alcoholic Steatohepatitis Market Segmentation, Forecasts and Trends - by Region

7. Company Market Share Analysis

8. Company Profiles

9. Industry Structure

10. Global Non-alcoholic Steatohepatitis Market - The Road Ahead

For more information about this report visit https://www.researchandmarkets.com/research/jtdh2c/nonalcoholic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181206005482/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/06/2018 08:59 AM/DISC: 12/06/2018 08:59 AM


Update hourly